Peruvoside

Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895) -resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib[1][2][3][4].

Product Specifications

CAS Number

[1182-87-2]

Product Name Alternative

Encordin

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Autophagy; EGFR; JNK; PI3K; Src; STAT

Type

Natural Products

Related Pathways

Apoptosis; Autophagy; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/peruvoside.html

Purity

99.32

Solubility

DMSO : ≥ 250 mg/mL

Smiles

O=C[C@@]([C@](C1)([H])CC2)(CC[C@@H]1O[C@H](O[C@H]3C)[C@H]([C@@H]([C@H]3O)OC)O)[C@](CC[C@@]45C)([H])[C@]2([H])[C@]4(CC[C@@H]5C(CO6)=CC6=O)O

Molecular Formula

C30H44O9

Molecular Weight

548.66

Precautions

H302, H315, H319, H335

References & Citations

[1]Lai Y, et al. Peruvoside is a novel Src inhibitor that suppresses NSCLC cell growth and motility by downregulating multiple Src-EGFR-related pathways. Am J Cancer Res. 2022 Jun 15;12 (6) :2576-2593.|[2]Reddy D, et al. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers. Life Sci. 2020 Jan 15;241:117147. doi: 10.1016/j.lfs.2019.117147. Epub 2019 Dec 9. PMID: 31830480.|[3]Feng Q, et al. Peruvoside, a Cardiac Glycoside, Induces Primitive Myeloid Leukemia Cell Death. Molecules. 2016 Apr 22;21 (4) :534.|[4]Wu KX, et al. The host-targeting compound peruvoside has a broad-spectrum antiviral activity against positive-sense RNA viruses. Acta Pharm Sin B. 2023 May;13 (5) :2039-2055.